S&P 500
5.469,30 +21,43 (+0,39%) Nasdaq
17.717,65 +220,84 (+1,26%) NIKKEI 225
39.693,41 +520,26 (+1,33%) Dólar/Euro
1,0708 -0,0008 (-0,07%) Petróleo Brent
85,43 +0,42 (+0,49%) Bitcoin EUR
57.557,47 +321,71 (+0,56%)
4D Molecular Therapeutics, Inc. (FDMT)
Después del cierre:
4D Molecular Therapeutics, Inc.
5858 Horton Street
Suite 455
EmeryVille, CA 94608
United States
510 505 2680
https://www.4dmoleculartherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 171
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. John F. Milligan Ph.D. | Executive Chairman | 150k | N/A | 1961 |
| Dr. David H. Kirn M.D. | Co-Founder, CEO & Director | 1,01M | N/A | 1963 |
| Dr. Fariborz Kamal Ph.D. | President & COO | 786,2k | N/A | 1963 |
| Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Officer | 201,29k | N/A | 1963 |
| Dr. Robert Y. Kim M.B.A., M.D. | Chief Medical Officer | 704,84k | N/A | 1961 |
| Ms. Theresa Janke | Co-Founder & Chief of Staff | 652,32k | N/A | 1975 |
| Mr. Uneek Mehra | Chief Financial & Business Officer | N/A | N/A | 1972 |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | N/A | N/A | 1973 |
| Dr. An Song Ph.D. | Chief Development Officer | N/A | N/A | N/A |
| Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D. | Senior VP & Therapeutic Area Head of Pulmonology | N/A | N/A | 1961 |
Descripción
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Gobierno corporativo
El ISS Governance QualityScore de 4D Molecular Therapeutics, Inc., a día 1 de junio de 2024, es 8. Las puntuaciones base son Auditoría: 3; Tablero: 6; Derechos de los accionistas: 8; Compensación: 9.
